文献速递儿童神经与发育行为儿童感染

孕期SARS-CoV-2 mRNA疫苗接种与18至30月龄儿童神经发育

SARS-CoV-2 mRNA Vaccination in Pregnancy and Child Neurodevelopment at 18 to 30 Months.
PubMed 文献 · JAMA Pediatr · 2026-11-02

这项多中心前瞻性队列研究纳入271名暴露和240名未暴露儿童,评估孕期或孕前30天内接种SARS-CoV-2 mRNA疫苗与子代18-30月龄神经发育的关联。结果显示暴露组与未暴露组ASQ-3总分等效(255 vs 260,校正中位差-3.4,90% CI -9.8至3.0),次级结局无显著差异,支持孕期继续推荐接种mRNA疫苗。

要点

  • 孕期或孕前30天内接种mRNA疫苗与子代18-30月龄ASQ-3总分等效。
  • 次级神经发育结局(ASQ-3各域、CBCL、M-CHAT、ECBQ)无显著差异。
  • 研究结果支持孕期继续推荐接种SARS-CoV-2 mRNA疫苗。

核心结论

  • 孕期或孕前30天内接种SARS-CoV-2 mRNA疫苗与子代18-30月龄ASQ-3总分等效。
  • 次级神经发育结局在暴露组与未暴露组间无显著差异。
  • 研究结果支持孕期继续推荐接种SARS-CoV-2 mRNA疫苗。

研究设计与样本

  • 多中心前瞻性队列研究,由Eunice Kennedy Shriver NICHD母胎医学单位网络14个中心于2024至2025年开展。
  • 暴露组为孕期或孕前30天内接种至少1剂SARS-CoV-2 mRNA疫苗的孕妇,按分娩地点、分娩日期、保险状态和种族 ethnicity 与未暴露组匹配。
  • 筛查3956人,纳入271名暴露和240名未暴露儿童,217对完成所有特征匹配,共434名儿童纳入分析。

主要发现

  • 暴露组与未暴露组ASQ-3总分分别为255和260,校正中位差-3.4(90% CI -9.8至3.0),达到等效标准。
  • 次级结局包括ASQ-3各域评分、儿童行为量表、改良版幼儿孤独症筛查量表和早期儿童行为问卷,均无显著差异。
  • 暴露组母亲更多为未产,其子代评估时年龄略小且更可能已接种SARS-CoV-2疫苗。

关键数值与推荐

  • ASQ-3总分等效标准为中位差的90% CI在-10至10之间,本研究结果为-3.4(90% CI -9.8至3.0),符合等效。

临床怎么用

  • 可为孕期咨询提供证据:孕期或孕前30天内接种SARS-CoV-2 mRNA疫苗未显示与子代18-30月龄神经发育不良关联。
  • 支持继续推荐孕期接种SARS-CoV-2 mRNA疫苗。

局限性

  • 暴露组与未暴露组在产次、子代评估年龄和子代SARS-CoV-2疫苗接种状态上存在差异。
  • 评估年龄范围为18-30月龄,不能外推至更远期神经发育结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Little is known about neurodevelopmental outcomes of children exposed to SARS-CoV-2 messenger RNA (mRNA) vaccine during pregnancy. Evidence on long-term offspring outcomes after in utero exposure to SARS-CoV-2 mRNA vaccination is needed to inform vaccine recommendations in pregnancy. OBJECTIVE: To evaluate whether there is an association between SARS-CoV-2 vaccination during or shortly before pregnancy and offspring neurodevelopmental measures. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, prospective, cohort study of 18- to 30-month-old children was conducted at 14 centers of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network from 2024 through 2025. Women who received a SARS-CoV-2 mRNA vaccine during or within 30 days prior to pregnancy (exposed) were matched with women who did not (unexposed) by delivery site, delivery date, insurance status, and race and ethnicity. These data were analyzed from June 2025 to May 2026. EXPOSURES: Maternal receipt of at least 1 dose of an mRNA SARS-CoV-2 vaccine during, or within 30 days prior to, the index pregnancy vs no SARS-CoV-2 vaccination during pregnancy or within 30 days prior. MAIN OUTCOMES AND MEASURES: The primary outcome was Ages and Stages Questionnaire version 3 (ASQ-3) total score, which was deemed to be equivalent between the exposed and unexposed groups if the 90% CI of the median difference was between -10 and 10. Secondary outcomes included domain-specific ASQ-3 scores, the Child Behavior Checklist, Modified Checklist for Autism in Toddlers, and Early Childhood Behavior Questionnaire scores. RESULTS: Of 3956 screened, 271 exposed and 240 unexposed children were enrolled. Matching on all characteristics was possible in 217 pairs. Of the 434 children enrolled, 258 (59.4%) were Non-Hispanic White, 96 (22.1%) Non-Hispanic Black, 52 (12.0%) Hispanic, and 28 (6.5%) were not represented by any of the above racial or ethnic groups. Median age at assessment was 25.8 [24.6 to 28.3] months, 221 were female (50.9%), and 213 were male (49.1%). Exposed mothers were more likely to be nulliparous; their children were slightly younger at assessment and more likely to have been vaccinated against SARS-CoV-2. The primary outcome of ASQ-3 score was equivalent between the exposed and unexposed groups (255 vs 260, adjusted median difference, -3.4; 90% CI, -9.8 to 3.0). There were no significant differences in secondary outcomes. CONCLUSIONS AND RELEVANCE: In this multicenter cohort study, ASQ-3 scores were equivalent between 18- to 30-month-old children whose mothers did or did not receive mRNA SARS-CoV-2 vaccination during or immediately prior to pregnancy. These findings support continued recommendations for SARS-CoV-2 mRNA vaccination during pregnancy.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Hughes BL, Clifton RG, Metz TD, et al. SARS-CoV-2 mRNA Vaccination in Pregnancy and Child Neurodevelopment at 18 to 30 Months. JAMA Pediatr. 2026. PMID: 42970265. doi:10.1001/jamapediatrics.2026.5142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。